Authors

E. David Crawford, MD, & Kyle O. Rove, MD

Latest:

Advanced Prostate Cancer: Therapeutic Sequencing, Outcomes, and Cost Implications

There is a dramatic revolution under way in the treatment of advanced-stage prostate cancer, which for many years consisted of systemic chemotherapy that offered only palliation of symptoms and no hope of improved survival.

E. David Crawford, MD, Neal D. Shore, MD

Latest:

Beyond PSA: A Summary Review of Predictive/Prognostic Biomarkers in Prostate Cancer

Although prostate cancer (PC) is the most common solid tumor malignancy among men in the Western Hemisphere, disease-specific mortality remains low, primarily due to optimized screening, diagnosis, and treatment.

E. David Crawford, MD, University of Colorado

E. David Crawford, MD, University of Colorado in Denver

E. Gabriela Chiorean, MD, FASCO

E. Gabriela Chiorean, MD, FASCO, is the clinical director of the GI Medical Oncology Program, professor in the Clinical Research Division, and affiliate investigator in the Translational Science and Therapeutics Division at Fred Hutchinson Cancer Center. She is also a professor of medicine at the University of Washington and director of the Clinical Research GI Oncology Program at the University of Washington/Fred Hutch.

Latest:

Dr Chiorean on Encorafenib Plus Cetuximab for BRAF V600E–Mutated mCRC

E. Gabriela Chiorean, MD, FASCO, discusses the FDA approval of encorafenib plus cetuximab and chemotherapy for patients with BRAF V600E–mutated mCRC.

E. Roy Berger, MD

Latest:

What to Look for in this Issue

The landscape for managing prostate cancer is changing rapidly. In recent months, we have seen two new drugs approved for hormone refractory advanced disease

E. Roy Berger, MD, FACP

Latest:

A Riddle, Wrapped in a Mystery, Inside an Enigma

At last year's American Society of Clinical Oncology (ASCO) meeting, the official focus was on seeing personalized cancer medicine translated from a theoretical approach to a practical one. As you will see in this issue of Oncology & Biotech News, success is being realized on this front.

Earle Burgess, MD

Latest:

Dr. Burgess on the Integration of PARP Inhibitors in Prostate Cancer

Earle Burgess, MD, discusses the integration of PARP inhibitors in advanced prostate cancer.

Ed Rabinowitz

Latest:

Rx for Protection Rather Than For Cure

Physicians tend to agree that the practice of defensive medicine is widespread, especially in oncology where much more is at stake than in the general practitioner's office. However, things can go drastically wrong.

Edgardo S. Santos, MD

Latest:

Dr. Santos on the Current Treatment Landscape in Squamous Cell Carcinoma of the Lung

Edgardo S. Santos, MD, FACP, discusses the current treatment landscape for patients with squamous cell carcinoma of the lung.

Edgardo S. Santos Castillero, MD, FACP, FASCO

Latest:

Amivantamab Toxicity Mitigation Strategies in the Treatment of EGFR-Mutant NSCLC

Panelists discuss how various strategies have been developed to enhance the tolerability of intravenous amivantamab, including premedication, step-up dosing, and infusion rate adjustments. Adoption into clinical practice varies, with many institutions integrating these approaches to mitigate infusion-related reactions and improve patient outcomes.

Edibaldo Silva, MD, PhD

Latest:

Back to the Future: Why Are More Women Having Bilateral Mastectomy for Unilateral Breast Cancer?

Since 2003, the rate of women choosing breast-conserving surgery for the management of early-stage breast cancer has declined, with an accompanying recidivism to mastectomy. Edibaldo Silva, MD, PhD, examines the reasons for the treatment regression.

Edith A. Perez, MD,

Latest:

Dr. Edith Perez on BOLERO-1 Results in HER2-Positive Breast Cancer

Edith Perez, MD, the deputy director at large for the Mayo Clinic Cancer Center, compares the results of the BOLERO-1 and BOLERO-3 trials.

Edith A. Perez, MD, Mayo Clinic

Edith Mitchell, MD, FACP

Latest:

Dr. Mitchell on ECOG-ACRIN’s Efforts in Addressing Health Disparities in Cancer Care

Edith P. Mitchell, MD, MACP, FCPP, FRCS, shared the inspiration behind the ECOG-ACRIN Health Equity Committee, and discusses ECOG-ACRIN’s efforts in addressing health disparities in cancer care.

Editorial Staff

Latest:

Top 5 Contagion® News Articles for the Week of August 27, 2017

Stay up-to-date on the latest infectious disease news by checking out this snapshot of our top 5 articles of the week.

Edouard J. Trabulsi, MD

Latest:

Dr. Trabulsi on Clinical Trial Combination Approaches in Prostate Cancer

Edouard J. Trabulsi, MD, FACS, professor, co-director, Multidisciplinary Genitourinary Oncology Center, Prostate Diagnostic Center, vice chair of research, director, Division of Urologic Oncology, Department of Urology, Sidney Kimmel Cancer Center, discusses clinical trials that are investigating combination approaches for patients with prostate cancer.

Edouard J. Trabulsi, MD, FACS

Latest:

Dr. Trabulsi Discusses Postoperative Radiation in Prostate Cancer

Edouard J. Trabulsi, MD, FACS, professor, co-director, Multidisciplinary Genitourinary Oncology Center, Prostate Diagnostic Center, vice chair of research, director, Division of Urologic Oncology, Department of Urology, Sidney Kimmel Cancer Center, discusses postoperative radiation in patients with prostate cancer.

Eduardo Fernandez, MD

Latest:

Hypofractionated and Stereotactic Body Radiotherapy in Prostate Cancer

Despite limited data comparing stereotactic body radiation therapy to standard or hypofractionated radiotherapy with regards to long-term clinical outcomes and toxicity profiles, the data are promising and appropriately selected patients can be offered such an approach off-protocol.

Eduardo Fernandez MD, PhD

Latest:

Daily and Cumulative Dose Recalculation and in Vivo Verification for Helical TomoTherapy: Multicenter Validation

Rapid advances in the technological development of precise and conformal radiation therapy and its incorporation into the clinic have generally outpaced our ability to test these technologies in a clinical trial format.